Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Pharmacokinetic and Pharmacogenetic Analysis of Bosutinib in Japanese Patients with Chronic-Phase Chronic Myeloid Leukemia

Akiko Mita, MD, Maiko Abumiya, PhD, Saori Takahashi, Ms, Yoshihiro Kameoka, MD PhD, Masatomo Miura, PhD, Naoto Takahashi, MD

Blood (2018) 132 (Supplement 1): 4271.

https://doi.org/10.1182/blood-2018-99-111905

Published: 2018

Journal Articles

Possibility of Lenalidomide Therapy and Determination of Its Ideal Dose for Patients with Relapsed or Refractory Multiple Myeloma

Seiji Shida, MD, Naoto Takahashi, MD, PhD, FJSIM, Masatomo Miura, PhD, Takenori Niioka, PhD, Morio Matsumoto, MD, Masao Hagihara, MD, Mutsuhito Motegi, MD, PhD, Masaaki Kume, MD, PhD, Jun Kuroki, MD, PhD, Atsushi Kitabayashi, MD, PhD, Yoshiaki Hatano, MD, PhD, Atsushi Watanabe, MD, PhD, Naohito Fujishima, MD, PhD, Yoshihiro Kameoka, MD, PhD, Hiroyuki Tagawa, MD, PhD, Makoto Hirokawa, MD, PhD, Kenichi Sawada, MD, PhD

Blood (2012) 120 (21): 4921.

https://doi.org/10.1182/blood.V120.21.4921.4921

Published: 2012

Journal Articles

CDR3-Independent Expansion of Vδ1 γδ T Lymphocytes and Depletion of Vδ2 T Cells Are Unique Features in Acquired Chronic Pure Red Cell Aplasia,

Michishita Yoshihiro, MD, Makoto Hirokawa, MD, PhD, Naohito Fujishima, MD, PhD, Yukiko Abe, Masumi Fujishima, MD, PhD, Yong-Mei Guo, MD, PhD, Kumi Ubukawa, MD, Liu Jiajia, MD, Tomoko Yoshioka, MD, PhD, Yoshihiro Kameoka, MD, PhD, Hirobumi Saitoh, MD, PhD, Hiroyuki Tagawa, MD, PhD, Naoto Takahashi, MD, PhD, Kenichi Sawada, MD, PhD

Blood (2011) 118 (21): 3429.

https://doi.org/10.1182/blood.V118.21.3429.3429

Published: 2011

Journal Articles

Safety, Feasibility and Efficacy of High Dose Ranimustine (MCNU), Carboplatin, Etoposide, and Cyclophosphamide (MCVC) Therapy Followed by Autologous Stem Cell Transplantation for Malignant Lymphoma.

Yoshihiro Kameoka, MD, PhD, Naoto Takahashi, MD, PhD, Kenichi Ishizawa, MD, PhD, Kazunori Murai, MD, PhD, Yuichi Kato, MD, PhD, Hideyoshi Noji, MD, PhD, Jugo Ito, MD, PhD, Makoto Hirokawa, MD, PhD, Katsusi Tajima, MD, PhD, Tsutomu Shichishima, MD, PhD, Yoji Ishida, MD, PhD, Hideo Harigae, MD, PhD, Kenichi Sawada, MD, PhD

Blood (2010) 116 (21): 4588.

https://doi.org/10.1182/blood.V116.21.4588.4588

Published: 2010

Journal Articles

Dasatinib Cerebrospinal Fluid Concentration and Plasma Pharmacokinetics: Potential for Central Nervous System Prophylaxis In Philadelphia Chromosome-Positive Leukemia

Naoto Takahashi, MD, PhD, Masatomo Miura, PhD, Stuart Scott, PhD, Hirobumi Saitoh, MD, PhD, Mutsuhito Motegi, MD, PhD, Naohito Fujishima, MD, PhD, Yoshihiro Kameoka, MD, PhD, Hiroyuki Tagawa, MD, PhD, Makoto Hirokawa, MD, PhD, Kenichi Sawada, MD, PhD

Blood (2010) 116 (21): 1807.

https://doi.org/10.1182/blood.V116.21.1807.1807

Published: 2010

Journal Articles

The Role of Mir-150 as a Tumor Suppressor In Malignant Lymphoma

Atsushi Watanabe,, MD, Hiroyuki Tagawa, MD, PhD, Kazuaki Teshima, MD, Yoshihiro Kameoka, MD, PhD, Naoto Takahashi, MD, PhD, Kenichi Sawada, MD, PhD

Blood (2010) 116 (21): 465.

https://doi.org/10.1182/blood.V116.21.465.465

Published: 2010

Journal Articles

MicroRNA-17-92 Downregulates Expression of Distinct Targets in Different B-Cell Lymphoma Subtypes

Hiroyuki Tagawa, MD, PhD, Mika Inomata, MD, Yong-Mei Guo, MD, Yoshihiro Kameoka, MD, PhD, Naoto Takahashi, MD, PhD, Kenichi Sawada, MD, PhD

Blood (2008) 112 (11): 5321.

https://doi.org/10.1182/blood.V112.11.5321.5321

Published: 2008

NARROW

Pharmacokinetic and Pharmacogenetic Analysis of Bosutinib in Japanese Patients with Chronic-Phase Chronic Myeloid Leukemia

Possibility of Lenalidomide Therapy and Determination of Its Ideal Dose for Patients with Relapsed or Refractory Multiple Myeloma

CDR3-Independent Expansion of Vδ1 γδ T Lymphocytes and Depletion of Vδ2 T Cells Are Unique Features in Acquired Chronic Pure Red Cell Aplasia,

Safety, Feasibility and Efficacy of High Dose Ranimustine (MCNU), Carboplatin, Etoposide, and Cyclophosphamide (MCVC) Therapy Followed by Autologous Stem Cell Transplantation for Malignant Lymphoma.

Dasatinib Cerebrospinal Fluid Concentration and Plasma Pharmacokinetics: Potential for Central Nervous System Prophylaxis In Philadelphia Chromosome-Positive Leukemia

The Role of Mir-150 as a Tumor Suppressor In Malignant Lymphoma

MicroRNA-17-92 Downregulates Expression of Distinct Targets in Different B-Cell Lymphoma Subtypes

Email alerts

ASH Publications

American Society of Hematology

Pharmacokinetic and Pharmacogenetic Analysis of Bosutinib in Japanese Patients with Chronic-Phase Chronic Myeloid Leukemia

Possibility of Lenalidomide Therapy and Determination of Its Ideal Dose for Patients with Relapsed or Refractory Multiple Myeloma

CDR3-Independent Expansion of Vδ1 γδ T Lymphocytes and Depletion of Vδ2 T Cells Are Unique Features in Acquired Chronic Pure Red Cell Aplasia,

Safety, Feasibility and Efficacy of High Dose Ranimustine (MCNU), Carboplatin, Etoposide, and Cyclophosphamide (MCVC) Therapy Followed by Autologous Stem Cell Transplantation for Malignant Lymphoma.

Dasatinib Cerebrospinal Fluid Concentration and Plasma Pharmacokinetics: Potential for Central Nervous System Prophylaxis In Philadelphia Chromosome-Positive Leukemia

The Role of Mir-150 as a Tumor Suppressor In Malignant Lymphoma

MicroRNA-17-92 Downregulates Expression of Distinct Targets in Different B-Cell Lymphoma Subtypes

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only